Clinical Trial Update: Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of brentuximab vedotin combined with BeEAM high-dose chemotherapy for lymphoma has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• BeEAM high-dose chemotherapy regimen
• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: Lymphoma | Phase 1, Phase 2 | Status: SUSPENDED